



---

CANCER PREVENTION & RESEARCH  
INSTITUTE OF TEXAS

**Oversight Committee Meeting  
August 16, 2017**

**Call to Order – Agenda Item 1**

A quorum being present, Presiding Officer Geren called the Oversight Committee to order at 10:01 a.m.

**Roll Call/Excused Absences – Agenda Item 2**

Committee Members Present:

Angelos Angelou  
Pete Geren  
Bill Rice, M.D.  
Will Montgomery  
Craig Rosenfeld, M.D.

Donald (Dee) Margo was not present at roll call, but arrived at 10:45 a.m. as noted in the minutes.

Absent:

Amy Mitchell  
Ned Holmes

**MOTION:**

On a motion made by Dr. Rice and seconded by Mr. Montgomery, the Oversight Committee unanimously voted to excuse the absence of Mr. Holmes and Mrs. Mitchell.

**Adoption of Minutes from the May 17, 2017, Meeting – Agenda Item 3**

**MOTION:**

On a motion made by Mr. Montgomery and seconded by Dr. Rice, the Oversight Committee unanimously voted to approve the minutes of the Oversight Committee meeting of May 17, 2017, as presented.

**Public Comment – Agenda Item 4**

Presiding Officer Geren noted that there were no requests for public comment.

**Grantee Presentations – Agenda Item 5**

Dr. James Willson, Chief Scientific Officer, introduced Dr. Peter Houghton, Professor, Molecular Medicine, The University of Texas Health Science Center at San Antonio, Director of the Greehey Children's Cancer Research Institute, and holder of the Greehey Distinguished Chair for the Children's Cancer Research Institute.

Dr. Houghton reported on the work of the Texas Pediatric PDX Core, a joint effort of The University of Texas Health Science Center at San Antonio and The University of Texas Southwestern Medical Center Dallas, and responded to questions from the Oversight Committee members.

Michael Lang, Chief Product Development Officer, introduced Fahar Merchant, Ph.D., Chairman, President and Chief Executive Officer of Medicenna BioPharma, Inc.

Dr. Merchant reported on the work of Medicenna BioPharma, Inc, and responded to questions from the Oversight Committee members.

### **Chief Executive Officer Report - Agenda Item 6**

Presiding Officer Geren called Mr. Wayne Roberts, Chief Executive Officer to give his report.

#### Personnel

Mr. Roberts reported all the agency's 32 positions are filled with permanent or contracted personnel. CPRIT expects to fill the three contracted positions with permanent employees on September 1 after the Governor's hiring moratorium expires. The three new positions authorized by the Legislature during the last session are posted and anticipated to be filled by the end of September.

#### Grant Awards Funds Available

Mr. Roberts noted that if the Oversight Committee approves all recommendations presented today, there will be \$2.6 million in available funds unspent for the year. The amount would have been only \$636,000 had an institution not declined a \$2 million recruitment award prior to this meeting. Mr. Roberts informed the Oversight Committee that in future years the agency will plan for a 1 to 1.5% reserve (equal to approximately \$2.8 to \$4 million) when budgeting for grant awards. Any unexpended balances in a fiscal year are rolled into the next fiscal year. Mr. Roberts stated he feels confident that by the time the agency Sunsets in 2023, all unexpended balances will be exhausted.

#### New Initiative

Mr. Roberts stated staff is exploring a complementary Request for Application (RFA) program related to the Academic Research Program. Because this is a new initiative and approach, Mr. Geren and Dr. Rice will participate in the scoping process. The stimulus for the initiative is Ms. Susan Dawson's presentation to the committee in February 2017 on a proposed new funding

mechanism. Mr. Roberts promised future updates for Oversight Committee members about this new initiative.

CPRIT Funding Scenarios through FY 2023

Mr. Roberts stated that the Legislature authorized the agency through FY 2023. He referred to three funding scenarios in the meeting materials that may inform the Oversight Committee when making program priority decisions.

Presiding Officer Geren noted for the record that Mr. Margo arrived at the meeting at 10:45.

**Chief Compliance Officer Report – Agenda Item 7**

Mr. Vince Burgess, Chief Compliance Officer, stated that his report in the meeting materials highlighted several compliance activities and initiatives, including Grant Recipient Reports, Financial Status Report Reviews, Desk Reviews, On-site Reviews, Annual Compliance Attestations, Single Audit Tracking, FY18 Grantee Risk and Assessment, and Training and Support. Mr. Burgess also noted that grantee delinquent/missing reports continue to be under the 5% threshold.

**Chief Scientific Officer Report and Grant Award Recommendations – Agenda Item 8**

Dr. James Willson, Chief Scientific Officer, presented the proposed awards recommended by the Program Integration Committee (PIC). He noted that the PIC recommended 52 awards, however a grant applicant withdrew one recruitment award after the PIC meeting but before the Oversight Committee meeting. Therefore, the Oversight Committee will consider 51 awards presented in 6 slates corresponding to grant mechanism and totaling approximately \$79,481,933. Dr. Willson also noted that the PIC recommendations include 8 Individual Research Awards (IIRA) totaling \$7,034,189, and 3 Early Translational Research Awards (ETRA) totaling \$2,998,914 that the PIC originally deferred at its October 28, 2016, meeting. To meet the FY17 budget allocation, Dr. Willson reported that the PIC recommended reducing the deferred IIRA and ETRA budgets by 8.5%.

Grant Mechanism	SRC Recommendations		Program Integration Committee Recommendations	
	Awards	Funding	Awards	Funding
Early Translational Research Awards (Deferred 17.1)	3	\$2,998,914	3	\$2,744,006
Individual Investigator Initiated Research Awards (Deferred 17.1)	8	\$7,034,189	8	\$6,436,283
High Impact/High Risk Research Awards	19	\$3,799,366	19	\$3,799,366
Core Facility Support Awards	7	\$30,502,278	7	\$30,502,278

Recruitment of Established Investigators	2	\$12,000,000	2	\$12,000,000
Recruitment of First-Time, Tenure Track Faculty Members*	13	\$26,000,000	13	\$26,000,000
<b>Total*</b>	<b>52</b>	<b>\$82,334,747</b>	<b>52</b>	<b>\$81,481,933</b>

\* The total includes one grant application, RR170064, which the PIC recommended for funding before the applicant withdrew the application.

<b>Program Priorities Addressed by Grant Recommendations</b>		
<b># Awards</b>	<b>Program Priorities</b>	<b>Funding</b>
15	Recruitment of outstanding cancer researchers to Texas	\$38,000,000
7	Investment in core facilities	\$30,502,278
30	A broad range of innovative, investigator-initiated research projects	\$12,979,656
5	Prevention and early detection	\$3,514,005
7	Computational biology and analytic methods	\$25,345,097
11	Childhood cancers	\$22,887,206
5	Cancers of importance in Texas	\$9,847,000
5	Disparities	\$8,138,500

\*Some grants awards address more than one program priority.

### Academic Research Grant Award Recommendations

<b>Core Facility Support Awards</b>					
<b>App ID</b>	<b>Award Mechanism</b>	<b>Application Title</b>	<b>PI</b>	<b>PI Organization</b>	<b>Recommended Budget</b>
RP170638	CFSA	Cyclotron and Radiochemistry Core Facility for Pediatric Oncology	Sun, Xiankai	The University of Texas Southwestern Medical Center	\$5,648,027
RP170644	CFSA	Establish a New Cryo-Electron Microscopy Core Facility and Service for Structure Determination at UT Southwestern Medical Center	Nicastro, Daniela	The University of Texas Southwestern Medical Center	\$5,498,714
RP170628	CFSA	The University of Texas M.D. Anderson Cancer Center Science	Richie, Ellen	The University of Texas M. D. Anderson	\$3,693,219

<b>Core Facility Support Awards</b>					
<b>App ID</b>	<b>Award Mechanism</b>	<b>Application Title</b>	<b>PI</b>	<b>PI Organization</b>	<b>Recommended Budget</b>
		Park Flow Cytometry and Cell Imaging Core		Cancer Center	
RP170691	CFSA	Patient-Derived Xenograft and Advanced in Vivo Models (PDX-AIM) Core Facility	Lewis, Michael	Baylor College of Medicine	\$3,822,860
RP170719	CFSA	GCC Center for Advanced Microscopy and Image Informatics	Mancini, Michael	Texas A&M University System Health Science Center	\$5,793,075
RP170675	CFSA	Individualized Pediatric Tumor Analysis Center of Texas (INPACT)	Allen, Carl	Baylor College of Medicine	\$200,000
RP170668	CFSA	Data Science and Informatics Core for Cancer Research	Zheng, Wenjin	The University of Texas Health Science Center at Houston	\$5,846,383

<b>High-Impact/High-Risk Research Awards</b>					
<b>App ID</b>	<b>Award Mechanism</b>	<b>Application Title</b>	<b>PI</b>	<b>PI Organization</b>	<b>Recommended Budget</b>
RP170674	HIHRA	Regulation of Cancer Cell Migration by Secreted Protein Phosphorylation	Tagliabracci, Vincent	The University of Texas Southwestern Medical Center	\$200,000
RP170640	HIHRA	Capitalizing on Therapeutic Liabilities in RAS-Mutant Cancers with a Rational Combination Therapy with PARP and MEK Inhibitors	Mills, Gordon	The University of Texas M. D. Anderson Cancer Center	\$200,000
RP170686	HIHRA	A Novel Chemical Strategy to Target EGFR for Destruction	Rao, Hai	The University of Texas Health Science	\$200,000

<b>High-Impact/High-Risk Research Awards</b>					
<b>App ID</b>	<b>Award Mechanism</b>	<b>Application Title</b>	<b>PI</b>	<b>PI Organization</b>	<b>Recommended Budget</b>
				Center at San Antonio	
RP170660	HIHRRRA	Optogenetic Toolkit for Precise Epigenome Editing in Cancer Cells	Zhou, Yubin	Texas A&M University System Health Science Center	\$200,000
RP170734	HIHRRRA	Mitochondrial DNA Instability Engages a Cancer-Related Interferon Program to Modify the Immune Microenvironment and NAD+ Metabolome and Enhance Melanoma Growth	West, Andrew	Texas A&M University System Health Science Center	\$199,795
RP170699	HIHRRRA	Targeting a Metabolic Reprogramming Event for the Early Prevention of Pancreatic Cancers	Tu, Benjamin	The University of Texas Southwestern Medical Center	\$200,000
RP170671	HIHRRRA	Targeting a Novel Nuclease PAAN in Triple-Negative Breast Cancer	Wang, Yingfei	The University of Texas Southwestern Medical Center	\$200,000
RP170714	HIHRRRA	Optimization of a Novel Class of Microtubule Stabilizers That Circumvent Multiple Drug Resistance Mechanisms Through Crystal-Structure Guided Total Synthesis	Frantz, Douglas	The University of Texas at San Antonio	\$200,000
RP170817	HIHRRRA	Isolation and in Situ Profiling of Circulating Tumor Cell Subpopulations Using a Hyperuniform Structured Microchip	Li, Wei	Texas Tech University	\$200,000
RP170633	HIHRRRA	The Role of the CACNA1D Calcium Channel in Melanoma	Morrison, Sean	The University of Texas Southwestern	\$199,828

<b>High-Impact/High-Risk Research Awards</b>					
<b>App ID</b>	<b>Award Mechanism</b>	<b>Application Title</b>	<b>PI</b>	<b>PI Organization</b>	<b>Recommended Budget</b>
				Medical Center	
RP170752	HIHRRRA	Radiation-Induced Release of Chemotherapeutic Agents in Vivo	Gassensmith, Jeremiah	The University of Texas at Dallas	\$200,000
RP170805	HIHRRRA	Etiology and Prevention of Gastric Cancers by Mitigation of H pylori Mechanosensing	Lele, Pushkar	Texas A&M University	\$200,000
RP170797	HIHRRRA	The Preparation of Novel Phage-Displayed Macrocyclic Peptide Libraries for the Identification of Anticancer Agents	Liu, Wenshe	Texas A&M University	\$200,000
RP170696	HIHRRRA	Targeting Cathepsin L as a Selective Mechanism for the Release of Potent Anticancer Agents from Drug-Linker Conjugates	Pinney, Kevin	Baylor University	\$200,000
RP170721	HIHRRRA	Enhancing Immunotherapy of Pancreatic Cancer by Disrupting Mutant K-Ras Using CRISPR/Cas9	Bao, Gang	Rice University	\$200,000
RP170619	HIHRRRA	An Unexpected Oncometabolic Axis: Exposing Novel Regulators of Cardiac Remodeling in Leukemia	Taegtmeier, Heinrich	The University of Texas Health Science Center at Houston	\$199,744
RP170747	HIHRRRA	Noninvasive Lung Cancer Screening by Rapid Chemical Profiling of Exhaled Breath	Sun, Yuze	The University of Texas at Arlington	\$199,999
RP170653	HIHRRRA	Identify Streptococcus gallolyticus Factors Important for Promoting Colorectal Tumor Development	Xu, Yi	Texas A&M University System Health Science Center	\$200,000
RP170722	HIHRRRA	Identification of Critical Dependencies and Actionable Therapeutic	Draetta, Giulio	The University of Texas M. D.	\$200,000

<b>High-Impact/High-Risk Research Awards</b>					
<b>App ID</b>	<b>Award Mechanism</b>	<b>Application Title</b>	<b>PI</b>	<b>PI Organization</b>	<b>Recommended Budget</b>
		Options in Smarcb1-Deficient Pediatric Tumors		Anderson Cancer Center	

<b>Previously Deferred Individual Investigator Research Awards and Early Translational Research Awards</b>					
<b>App ID</b>	<b>Award Mechanism</b>	<b>Application Title</b>	<b>PI</b>	<b>PI Organization</b>	<b>Recommended Budget</b>
RP170373	IIRA	HTS for covalent GTP-competitive inhibitors of KRAS G12C	Westover, Kenneth	The University of Texas Southwestern Medical Center	\$823,500
RP170086	IIRA	Tumor suppression, p53 and retrotransposons	Abrams, John	The University of Texas Southwestern Medical Center	\$816,171
RP170572	IIRA	Probing Novel Concepts of the NF-kappaB Transcriptional Program In Human Cancer	D'Orso, Ivan	The University of Texas Southwestern Medical Center	\$679,458
RP170267	IIRA	Chemically based disruption of oncogenic beta-catenin activity in liver tissue	Lum, Lawrence	The University of Texas Southwestern Medical Center	\$823,500
RP170407	IIRA	Role of HDAC8 and higher order chromatin structure in melanoma metastasis and therapy	Rai, Kunal	The University of Texas M.D. Anderson Cancer Center	\$823,154
RP170179	ETRA	Chemoablation of High-Risk Oral Premalignant Lesions for Sustained Cancer Prevention	Tsai, Robert	Texas A&M University System Health Science Center	\$915,000
RP170500	ETRA	Development of next generation steroid receptor coactivator small molecule inhibitors as novel agents to target therapy-resistant breast cancer	O'Malley, Bert	Baylor College of Medicine	\$914,006
RP170090	IIRA	Novel Regulation and Function of TAK1 in	Chiao, Paul	The University of Texas M.D.	\$823,500



<b>Previously Deferred Individual Investigator Research Awards and Early Translational Research Awards</b>					
<b>App ID</b>	<b>Award Mechanism</b>	<b>Application Title</b>	<b>PI</b>	<b>PI Organization</b>	<b>Recommended Budget</b>
		Mutant Kras-driven Development of Pancreatic Ductal Adenocarcinoma		Anderson Cancer Center	
RP170333	ETRA	Targeting ubiquitination for cancer therapy	Zhang, Shuxing	The University of Texas M.D. Anderson Cancer Center	\$915,000
RP170180	IIRA	Mechanistic Roles of Long Non-Coding RNA in Glioblastoma Development and Treatment	Huang, Suyun	The University of Texas M.D. Anderson Cancer Center	\$823,500
RP170172	IIRA	Targeting Therapy Resistance using Epithelial to Mesenchymal Transition (EMT) Pathways in Preclinical Claudin Low Breast Cancer Models	Rosen, Jeffrey	Baylor College of Medicine	\$823,500

<b>Academic Research Recruitment Grant Awards</b>				
<b>App ID</b>	<b>Candidate</b>	<b>Mechanism</b>	<b>Organization</b>	<b>Budget</b>
RR170048	Amos, Christopher	REI	Baylor College of Medicine	\$6,000,000
RR170063	Woodruff, Jeffrey	RFTFM	The University of Texas Southwestern Medical Center	\$2,000,000
RR170079	Li, Bo	RFTFM	The University of Texas Southwestern Medical Center	\$2,000,000
RR170061	Arteaga, Carlos	REI	The University of Texas Southwestern Medical Center	\$6,000,000
*RR170064	Obeng, Esther	RFTFM	The University of Texas Southwestern Medical Center	\$2,000,000
RR170076	Wu, Jun	RFTFM	The University of Texas Southwestern Medical Center	\$2,000,000

RR170054	Dickinson, Daniel	RFTFM	The University of Texas at Austin	\$2,000,000
RR170059	Tsai, Kuang-Lei	RFTFM	The University of Texas Health Science Center at Houston	\$2,000,000
RR170068	Kim, Daehwan	RFTFM	The University of Texas Southwestern Medical Center	\$2,000,000
RR170051	Aguilera, Todd	RFTFM	The University of Texas Southwestern Medical Center	\$2,000,000
RR170047	Hancks, Dustin	RFTFM	The University of Texas Southwestern Medical Center	\$2,000,000
RR170055	Zheng, Siyuan	RFTFM	The University of Texas Health Science Center at San Antonio	\$2,000,000
RR170075	Reddy, Rohith	RFTFM	University of Houston	\$2,000,000
RR170062	Uribe, Rosa	RFTFM	Rice University	\$2,000,000
RR170050	Mu, Ping	RFTFM	The University of Texas Southwestern Medical Center	\$2,000,000

\* RR170064 recommended by the PIC was withdrawn by the applicant after the PIC meeting.

### Compliance Certification

Mr. Vince Burgess, Chief Compliance Officer, presented his certification of the review process for the proposed Academic Research Awards, Prevention Awards, and Product Development Research Awards recommendations presented to the Oversight Committee at this meeting. He stated he had reviewed the compliance pedigrees for the grant applications submitted to CPRIT for the six Academic Research Award mechanisms, the one Product Development Research Award mechanism, and four Prevention Award mechanisms. Further, Mr. Burgess stated he had conferred with staff at CPRIT and CSRA, International (CSRA), CPRIT's contracted third-party grants administrator and studied the supporting grant review documentation, including third-party observer reports for the peer review meetings.

Mr. Burgess reported he was satisfied that the application review process that resulted in the above mechanisms recommended by the PIC followed applicable laws and agency administrative rules and certified the award recommendations for the Oversight Committee's consideration.

### Conflict of Interest Notification

Presiding Officer Geren noted for the record that Mr. Angelou has reported a conflict of interest with the awards recommended for The University of Texas at Austin.

### Vote on Recommended Awards

Presiding Officer Geren noted for the record that the applicant withdrew application RR170064 after the PIC meeting. That award recommendation is not included as part of the awards voted on by the Oversight Committee.

**MOTION:**

On a motion made by Mr. Margo and seconded by Dr. Rice, the Oversight Committee unanimously voted to approve the PIC's recommendation for RR170054 to The University of Texas at Austin.

Presiding Officer Geren noted for the record that Mr. Angelou did not vote on this recommendation.

**MOTION:**

On a motion made by Mr. Margo and seconded by Mr. Montgomery, the Oversight Committee unanimously voted to approve the PIC's recommendations for the remaining 50 academic research awards.

**MOTION:**

On a motion made by Mr. Margo and seconded by Dr. Rice, the Oversight Committee unanimously voted to approve the delegation of contract negotiation authority to the Chief Executive Officer and CPRIT staff, and authorized the Chief Executive Officer to sign the contracts on behalf of CPRIT.

Program Priorities Impact Report and Active and Proposed Academic Research RFA Mechanisms FY18 and FY19.1

Dr. Willson presented the Program Priorities Impact report for 2015 – 2017 academic research awards and made several observations:

- The CPRIT portfolio represents the priorities of “Cancers of Importance in Texas” as evidenced by the academic research community’s work done in lung, liver, and cervical cancer. The number of awards represented in the program priorities chart is low because the chart only covers the preceding six months.
- Seventeen percent of the academic research awards have been made in the priority area of “Disparities,” and more work will continue in this area. CPRIT has ongoing initiatives with strategies to stimulate accrual in traditionally under-represented populations.
- In prevention and early detection, Texas has strong prevention research programs throughout the state, yet prevention does not see the same number of applications as from traditional biology. To stimulate those applications, CPRIT initiated a targeted RFA and assembled a targeted panel to review the resulting applications. CPRIT encourages communities that are addressing prevention service delivery to think about ways to interact with the academic researchers. A recent RFA under review now includes a

special call for taking advantage of population demonstration projects supported by CPRIT's Prevention Program.

Dr. Willson responded to a question about quantifying the residual benefits of academic research awards, noting that CPRIT could use statistics such as NIH grant dollars, the number of corporate grants or graduate students that CPRIT research grantees bring to Texas. For instance, to date 135 CPRIT scholars who have come to Texas have brought follow-on funding that exceeds \$225 million. A less tangible but important parameter to consider is the halo effect of the reputations that these individuals have when they bring their already achieved recognition with them to Texas.

Transitioning to the presentation of proposed FY 2018 and FY 2019 requests for applications (RFAs), Dr. Willson stated that since CPRIT has limited funding available for awards, staff seeks the Oversight Committee's input regarding RFAs with consideration of realistic budget projections. He restated the 2017 Academic Research Program Priorities and discussed the announced and proposed RFAs for FY 2018.

FY 2018 Academic Research Requests for Applications

- Recruitment of Established Investigators (FY18)
- Recruitment of Rising Stars (FY18)
- Recruitment of First-Time Tenure Track Faculty Members (FY18)
- Core Facilities Support Awards (CFSA) (RFA R-18.2 CFSA)
- High Impact/High Risk Research Awards (HIHR) (RFA R-18.2 HIHR)
- Early Translational Awards (ETA) (RFA-R-18.2 ETA)

For the purposes of discussion, Dr. Willson projected the anticipated budgets for the announced and proposed FY 2018 RFAs.

<u>Announced RFA Mechanisms</u>	<u>Anticipated Budget</u>
Recruitment (25-30 @ 2,000,000 - 6,000,000)	\$80,000,000
Individual Investigator Research Award (IIRA)	\$45,600,000
IIRA - Individual Investigator Research Awards (18 @ 900,000)	\$16,200,000
IIRA - Childhood & Adolescent Cancers (6 @ 1,000,000)	\$6,000,000
IIRA - Computational Biology (6 @ 900,000)	\$5,400,000
IIRA - Prevention & Early Detection (6 @ 1,000,000)	\$6,000,000
IIRA - Clinical Translation (6 @ 2,000,000)	<u>\$12,000,000</u>

<u>Proposed RFA Mechanisms</u>	<u>Anticipated Budget</u>
Core Facilities Support Award (6 @ 6,000,000)	\$36,000,000

High Impact/High Risk (20 @ 200,000)	\$4,000,000
Early Translational Award (5 @ 2,000,000)	\$10,000,000
Multi-Investigator Research Award (4 @ 6,000,000)	<u>\$24,000,000</u>
<b>Total Announced &amp; Proposed</b>	<b><u>\$199,600,000</u></b>

Presiding Officer Geren clarified that the Oversight Committee’s vote on the direction of the FY 2018 - 2019 RFAs would not be a vote for or against the anticipated budgeted amounts as presented by Dr. Willson. Those budget amounts will vary according to applications received and recommendations made in each of the program areas, and according to on-going discussions among the professional staff and the Oversight Committee.

Mr. Roberts added that CPRIT has funded all projects that the peer reviewers and the PIC have recommended so far. In some years, CPRIT has scheduled a special September meeting to approve some of the proposed grants to take advantage of the start of a new fiscal year. CPRIT has also made funding adjustments at the time of award approval for some grants when the adjustments do not affect the viability of the projects.

Discussing the split between academic research and product development research funding, Mr. Roberts referenced an Oversight Committee workshop on May 19, 2016. At that meeting the Oversight Committee did not set a formal funding allocation for each program but instead stated the intent that CPRIT fund more product development awards than previously. Historically the funding split was 80% academic research and 20% product development research. Mr. Roberts reported that internal targets set over the course of the last two years projected product development funding at 25% to 30% of the annual award budget, respectively. CPRIT did not reach the 30% target for product development in FY 2017. As a result, CPRIT was able to fund recommendations for academic research awards that exceeded the original FY 2017 target of 70% of the annual award budget. Mr. Roberts noted that while he is not concerned about CPRIT’s ability to fund recommendations in the coming fiscal year, he is watching the number of product development applications that make it through the peer review process for indication of a trend or a one-time event. It is a testament to the peer review process that the review panels are not recommending applications just to meet a funding quota.

Dr. Willson responded to a question, explaining that CPRIT did not list the “population disparities and cancers of importance in Texas” separately as a RFA mechanism because this priority is integrated into all RFAs.

An Oversight Committee member expressed the desire to have further discussion on funding Early Translational Research Awards (ETRA) with CPRIT monies before voting on an RFA. Another member suggested holding a meeting with CPRIT staff and interested Oversight Committee members to discuss the proposed ETRA RFA further and bringing the results to a future Oversight Committee meeting.

**MOTION:**

On a motion made by Mr. Montgomery and seconded by Mr. Margo, the Oversight Committee unanimously voted to approve the Academic Research Program's plan for active and proposed Requests for Applications (RFAs) for FY 2018 and early 2019, except for Early Translation Research RFAs.

### **Internal Auditor Report - Agenda Item 16**

Ms. Alyssa Martin and Daniel Graves, Internal Auditors, presented the Internal Audit Reports on Pre-Award Grant Management and on Procurement and P-Cards. Additionally, Ms. Martin presented follow-up procedures reports for three previous audits in which CPRIT had remediated all findings.

Ms. Martin presented the Fiscal Year 2017 Annual Internal Report for approval of the Oversight Committee. She reported that the Audit Subcommittee reviewed the annual report.

Ms. Martin indicated that the last issue to discuss with the Oversight Committee was the follow up procedures on the internal audit on information security.

### Closed Session

Pursuant to the Texas Open Meetings Act, Section 551.076, Presiding Officer Geren announced that the Oversight Committee would move into closed session to discuss a security audit. Presiding Officer Geren asked Alyssa Martin and Dan Graves (Internal Auditors), Heidi McConnell, Kristen Doyle, Therry Simien, and Wayne Roberts to join the Oversight Committee in the closed session.

Presiding Officer Geren convened in closed session at 1:15 p.m.

Presiding Officer Geren reconvened the open meeting at 2:11 p.m.

Presiding Officer Geren stated the Audit Subcommittee met on August 7, 2017, and recommended the Oversight Committee approve the audits and annual report.

#### **MOTION:**

On a motion made by Mr. Angelou and seconded by Mr. Montgomery, the Oversight Committee unanimously voted to approve the internal audit on Pre-Award Grant Management and the internal audit on Procurement and P-Cards and the four follow up procedures for prior year audit findings.

#### **MOTION:**

On a motion made by Dr. Rosenfeld and seconded by Dr. Rice, the Oversight Committee unanimously voted to approve CPRIT's Fiscal Year 2017 Annual Internal Report.

### **Chief Prevention and Communications Officer Report - Agenda Item 9**

Prevention Program Awards Recommendations

Dr. Rebecca Garcia, Chief Prevention and Communications Officer, reported that the PIC recommended eight projects totaling \$14,019,137 for approval. She presented the grant recommendations in 4 slates. Dr. Garcia noted that the PIC agreed with the Prevention Review Council’s recommendation to reduce all budgets by 10% to assure that sufficient funds are available to support all recommended applications for this cycle. She also noted that the Competitive Continuation/Expansion award was a deferred application.

Mr. Margo reported that the Prevention Subcommittee recommended that the Oversight Committee approve the four Prevention slates.

# of Apps Recommended	Grant Mechanism Slate	Award Amount
2	Colorectal Cancer Prevention Coalition	\$ 5,972,794
1	Competitive Continuation/Expansion for Evidence-Based Cancer Prevention Services	\$ 1,350,000
3	Evidence-Based Cancer Prevention Services	\$ 4,044,851
2	Tobacco Control and Lung Cancer Screening	\$ 2,651,492

<b>Number of Recommended Applications* Addressing Priorities</b>	
5	Prioritize populations disproportionately affected by cancer incidence, mortality, or cancer risk prevalence
5	Prioritize geographic areas of the state disproportionately affected by cancer incidence, mortality, or cancer risk prevalence
8	Prioritize underserved populations

\* Some applications fulfill more than one priority.

<b>Prevention Program Awards Recommendations</b>					
App ID	Mech.	Application Title	PD	Organization	Rec Budget
PP170094	EBP	Expanding a Community Network for Cancer Prevention to Improve Cervical and Colorectal Screening and Follow-Up Among an Urban Medically Underserved Population	Jibaja-Weiss, Maria L	Baylor College of Medicine	\$1,347,590
PP170068	CRC	Southwest Coalition for Colorectal Cancer Screening (SuCCCeS)	Shokar, Navkiran K	Texas Tech University Health Sciences Center at El Paso	\$3,679,823

<b>Prevention Program Awards Recommendations</b>					
<b>App ID</b>	<b>Mech.</b>	<b>Application Title</b>	<b>PD</b>	<b>Organization</b>	<b>Rec Budget</b>
PP170070	TCL	Taking Texas Tobacco Free: Increasing Tobacco Cessation in Substance Use Treatment Centers via an Evidence-based, Comprehensive Tobacco-free Workplace Program	Reitzel, Lorraine R	University of Houston	\$1,348,851
PP170082	CRC	Improving Colorectal Cancer Screening in Vulnerable Populations in Travis County	Pignone, Michael	The University of Texas at Austin	\$2,292,971
PP170099	TCL	Mobile Cessation Services for Young Adult Rural, Low-Income, and Spanish-Speaking Smokers	Ramirez, Amelie G	The University of Texas Health Science Center at San Antonio	\$1,302,641
PP170088	EBP	Access to Breast and Cervical Care for West Texas (ABC24WT)	Layeequr Rahman, Rakhshanda	Texas Tech University Health Sciences Center	\$1,349,730
PP170091	EBP	Empower Her To Care Expansion(EHC4): Increasing Access to Breast Cancer Screening and the Continuum of Care for Underserved Texas Women	Joseph, Bernice	The Rose	\$1,347,531
PP170037 Deferred from 17.1	CCE-EBP	Continuation/Expansion of Texas A&M's Breast and Cervical Cancer Prevention Program for Underserved Women through a Family Medicine Residency	McClellan, David A	Texas A&M University System Health Science Center	\$1,350,000

Compliance Certification

Presiding Officer Geren noted that Mr. Burgess previously certified compliance of the Prevention awards process.

Conflict of Interest Notification



Presiding Officer Geren indicated that Mr. Angelou reported a conflict of interest with application PP170082 submitted by The University of Texas at Austin.

#### Vote on Recommended Awards

**MOTION:**

On a motion made by Mr. Montgomery and seconded by Dr. Rice, the Oversight Committee unanimously voted to approve the Program Integration Committee's recommendation for PP170082 to The University of Texas at Austin.

Presiding Officer Geren noted for the record that Mr. Angelou did not vote on this recommendation.

**MOTION:**

On a motion made by Mr. Margo and seconded by Mr. Montgomery, the Oversight Committee unanimously voted to approve the Program Integration Committee's recommendations for the remaining 7 prevention awards.

**MOTION:**

On a motion made by Mr. Margo and seconded by Mr. Montgomery, the Oversight Committee unanimously voted to approve the delegation of contract negotiation authority to the Chief Executive Officer and CPRIT staff, and authorized the Chief Executive Officer to sign the contracts on behalf of CPRIT.

#### Program Priorities Impact Report and Active and Proposed Prevention RFA Mechanisms for FY 2018

Dr. Garcia presented the Program Priorities Impact Report for the Prevention Program and directed the Oversight Committee to the report under Item 11 in their agenda books.

She reported that FY 2018 Cycle 1 is underway. CPRIT released three RFAs for this cycle:

- Evidence-Based Cancer Prevention Services
- Tobacco Control and Lung Cancer Screening
- Dissemination of CPRIT-Funded Cancer Control Intervention (DI)

Dr. Garcia indicated that the DI RFAs will be continuously open and the Prevention Review Council will generally review applications on a quarterly basis in order to expedite the dissemination of successful CPRIT funded projects. CPRIT will present successful applications to the Oversight Committee at a scheduled quarterly meeting.

Dr. Garcia presented the proposed FY 2018 Cycle 2 RFA, "Expansion of Cancer Prevention Services to Rural (nonmetropolitan) and Medically Underserved Areas." She reported that this is a new RFA to encourage applicants to add a service to a CPRIT project currently in progress, such as adding cervical cancer services to a breast cancer screening project, with a requirement that the services be delivered to those from medically underserved and rural areas of the state.

She noted that other mechanisms under consideration for FY 2018 Cycle 2 RFAs are:

- Evidence-Based Cancer Prevention Services
- Tobacco Control and Lung Cancer Screening
- Dissemination of CPRIT-Funded Cancer Control Interventions (DI)

Dr. Garcia will notify the Oversight Committee through the Prevention Subcommittee about the intention to release any RFAs after assessing the type and volume of applications submitted for Cycle FY18.1. She noted that these are RFAs that CPRIT has released in the past and are updated about a month before the next release.

Presiding Officer Geren noted that the county-by-county data grantees are now reporting and the new Expansion RFA will allow the CPRIT Oversight Committee and staff to examine the services provided in rural areas of the state more closely.

Presiding Officer Geren also noted that Dr. Willson presented RFAs for FY 2018 and FY 2019, while Dr. Garcia presented for FY 2018.

**MOTION:**

On a motion made by Mr. Montgomery and seconded by Mr. Margo, the Oversight Committee unanimously voted to approve the Prevention Program’s plan for active and proposed Requests for Applications (RFAs) for FY 2018.

Communications Program Update

Dr. Garcia stated that registration for the conference opened at the end of July. By August 15, 76 people registered, and 204 abstracts were submitted. Staff is working with speakers to finalize the titles and descriptions of their topics.

**Chief Product Officer Report and Grant Awards Recommendations - Agenda Item 10**

Mr. Michael Lang, Chief Product Development Officer, reported that CPRIT received 20 applications for the FY 17.2 review cycle. CPRIT invited six applicants to make in-person presentations, and peer reviewers selected two for due diligence. The Review Council recommended one for a grant award, which the PIC has also for Oversight Committee approval.

For the FY 18.1 review cycle, CPRIT received 19 applications and the review process will be starting.

Dr. Rosenfeld reported that the Product Development Subcommittee reviewed this application and recommended approval.

**Product Development Research Awards Recommendations**

<b>Application ID</b>	<b>Company Name</b>	<b>Project</b>	<b>Maximum Recommended Budget</b>
-----------------------	---------------------	----------------	-----------------------------------

DP170043	ViraCyte, LLC	Improving the Outcome of Stem Cell Transplants for Cancer Treatment Using Multi-Virus Specific T cells	\$8,998,067
----------	---------------	--	-------------

Compliance Certification and Conflict of Interest Notification

Presiding Officer Geren noted that Mr. Burgess had previously certified compliance of the Product Development Awards process and that no member had reported a conflict of interest.

Vote on Recommended Award

**MOTION:**

On a motion made by Mr. Angelou and seconded by Dr. Rosenfeld, the Oversight Committee unanimously voted to approve the Program Integration Committee’s recommendation for ViraCyte, LLC.

**MOTION:**

On a motion made by Mr. Montgomery and seconded by Dr. Rosenfeld, the Oversight Committee unanimously voted to approve the delegation of contract negotiation authority to the Chief Executive Officer and CPRIT staff, and authorized the Chief Executive Officer to sign the contracts on behalf of CPRIT.

**MOTION:**

On a motion made by Mr. Montgomery and seconded by Mr. Angelou, the Oversight Committee unanimously voted to authorize CPRIT to disburse grant funds via advance payments to ViraCyte, LLC, upon execution of the award contract and the successful completion of tranches, pursuant to the General Appropriations Act, Article IX, Section 4.03(a).

**Contract Approvals - Agenda Item 21**

Chief Operating Officer Heidi McConnell presented staff’s recommendation that the Oversight Committee approve the following contracts for FY 2018:

- Contract renewal with The Perryman Group for \$150,000 to perform an internal audit assessment of the cost of cancer in Texas.
- Contract renewal with Weaver and Tidwell for \$243,750 to provide internal audit services; and
- Contract renewal with Hahn Public Communications for \$149,975 to provide strategic communications services.

Ms. McConnell noted that the contracts for the Oversight Committee’s consideration are not-to-exceed amounts, and payment is based on the delivery of actual services from the vendor, either time and materials or a unit cost. She also noted that the renewal of the Weaver and Tidwell contract will require the State Auditor’s Office to provide audit delegation authority to CPRIT prior to contract execution.

There were no questions for Ms. McConnell.

**MOTION:**

On a motion made by Mr. Montgomery and seconded by Dr. Rice, the Oversight Committee unanimously voted to approve FY 2018 contracts with The Perryman Group, Weaver and Tidwell, and Hahn Public Communications.

**Mirna Shareholder Vote - Agenda Item 19**

Ms. Kristen Doyle, Deputy Executive Officer and General Counsel, reported that Mirna Therapeutics announced in May plans to merge with Synlogic, Inc., via a reverse merger arrangement to maximize value for its shareholders. There will be an annual shareholder meeting on August 24, 2017, to vote on approval of the merger. CPRIT is a shareholder via the revenue sharing agreement in Mirna's award contract. Ms. Doyle presented staff's request that the Oversight Committee delegate authority to the Chief Executive Officer to vote CPRIT's shares at the annual meeting.

**MOTION:**

On a motion made by Dr. Rice and seconded by Mr. Montgomery, the Oversight Committee unanimously voted to delegate authority to CPRIT's Chief Executive Officer to take all actions necessary to vote CPRIT's shares in Mirna at the company's upcoming annual shareholder meeting.

**Amendments to 25 T.A.C. Chapter 703 - Agenda Item 17**

Ms. Cameron Eckel, Staff Attorney, presented the following rules changes for Oversight Committee action:

- Final approval of a rule change first presented at the May 2017, Oversight Committee meeting that eliminates the fifth reporting period for grantees. Ms. Eckel reports that CPRIT received no public comments regarding the proposed rule change.
- Approval to publish two proposed rule changes in the *Texas Register* to seek public comment. Ms. Eckel reports that one change clarifies that grantees need to maintain grant records for a period of three years and one change prohibits grantee payments to a subcontractor that employs a relative of the grantee unless CPRIT grants an exception.

**MOTION:**

On a motion made by Mr. Montgomery and seconded by Mr. Margo, the Oversight Committee unanimously voted to approve the final orders adopting rule change to the Texas Administrative Code Chapters 703.

**MOTION:**

On a motion made by Mr. Angelou and seconded by Mr. Margo, the Oversight Committee unanimously voted to approve the proposed changes to Texas Administrative Code Chapter 703 for publication in the *Texas Register*.

### **1. Subcommittee Business - Agenda Item 22**

Presiding Officer Geren presented the Board Governance Subcommittee's proposed subcommittee assignments for FY 2018-2019 for Oversight Committee approval. He noted that CPRIT provided the proposed assignments in the Oversight Committee meeting packet.

**MOTION:**

On a motion made by Mr. Montgomery and seconded by Mr. Angelou, the Oversight Committee unanimously voted to approve the new subcommittee assignments for FY 2018-2019.

### **Election of Board Officers - Agenda Item 23**

Presiding Officer Geren reported that the Nominations Subcommittee unanimously recommended the following slate of officers:

Will Montgomery – Presiding Officer  
Dee Margo – Vice Presiding Officer  
Amy Mitchell - Secretary

**MOTION:**

On a motion made by Mr. Angelou and seconded by Dr. Rice, the Oversight Committee unanimously voted to approve the slate of officer recommendations: Will Montgomery as Presiding Officer, Dee Margo as Vice Presiding Officer, and Amy Mitchell as Secretary.

### **Special Resolution Honoring Outgoing Chair Pete Geren**

Mr. Montgomery presented a resolution from the Oversight Committee honoring the service of Mr. Geren as Presiding Officer for Fiscal Years 2016-2017.

### **Health & Safety Code Section 102.1062 Waivers - Agenda Item 14**

Mr. Roberts presented a request for conflict of interest waivers for Dr. Rebecca Garcia, Dr. John Hellerstedt, Mr. Don Brady, Mr. Will Montgomery, and Ms. Amy Mitchell.

**MOTION:**

On a motion made by Mr. Angelou and seconded by Mr. Montgomery, the Oversight Committee unanimously voted to approve the requested conflict of interest waivers pursuant to Health & Safety Code Section 102.1062.

### **Scientific Research and Prevention Program Comm. Appointments - Agenda Item 12**

Mr. Roberts presented the list of four appointees to CPRIT review panels for Oversight Committee approval. He stated the Nominations Subcommittee discussed the appointments and recommended approval.

**MOTION:**

On a motion made by Mr. Angelou and seconded by Mr. Montgomery, the Oversight Committee unanimously voted to approve the Scientific Research Program Committee appointments.

**FY 2018 Honoraria Policy - Agenda Item 13**

Mr. Roberts presented the proposed honoraria policy for FY 2018 for Oversight Committee approval. He reported that the policy was the same as the honoraria policy for FY 2017.

**MOTION:**

On a motion made by Mr. Angelou and seconded by Dr. Rice, the Oversight Committee unanimously voted to approve the FY 2018 honoraria policy.

**Resolution Transferring Management Authority to the Texas Treasury Safekeeping Trust Company - Agenda Item 15**

Ms. Kristen Doyle, Deputy Executive Officer and General Counsel, presented a resolution transferring management authority to the Texas Treasury Safekeeping Trust Company and delegating authority to the Chief Executive Officer to take necessary actions to complete the transfer of certain assets, including negotiating a fee for the Trust Company's reasonable and necessary expenses involved with managing the transferred assets.

Presiding Officer Geren introduced Mr. Paul Ballard, Chief Executive Officer and Chief Investment Officer of the Texas Treasury Safekeeping Trust Company to provide background on the Trust Company. There were no questions for Mr. Ballard.

**MOTION:**

On a motion made by Mr. Angelou and seconded by Dr. Rice, the Oversight Committee unanimously approved the resolution transferring management authority to the Texas Treasury Safekeeping Trust Company for the assets named in the resolution.

**Amendment to the Oversight Committee Bylaws - Agenda Item 18**

Ms. Doyle presented the Board Governance Subcommittee's recommended changes to the bylaws and the Code of Conduct regarding new member training. She noted that one change provides for a 30-business day deadline to complete new member training. The other change allows a new member to participate in Oversight Committee meetings before completing the required training, with the exception that they cannot vote on awards until conflict of interest training is completed.

**MOTION:**

On a motion made by Dr. Rosenfeld and seconded by Mr. Angelou, the Oversight Committee unanimously voted to approve the proposed changes to the Oversight Committee bylaws and Code of Conduct.

**Program Priorities - Agenda Item 11**

Presiding Officer Geren stated item will be added to the November 2017 Oversight Committee meeting agenda.

**Chief Operating Officer Report - Agenda Item 20**

Ms. McConnell stated her report was in the Oversight Committee meeting materials along with the CPRIT's Operating Budget for 2018. There were no questions for Ms. McConnell.

**Compliance Investigation Pursuant to Health & Safety Code § 102.2631; Consultation with General Counsel - Agenda Items 24 and 25**

The Oversight Committee did not discuss items 24 and 25.

**Future Meeting Dates - Agenda Item 26**


Presiding Officer Geren announced that CPRIT has moved the next regular Oversight Committee meeting to November 29, 2017, due to CPRIT's upcoming biennial conference. Subcommittee meetings will remain on their regular schedule for the November meeting.


**Adjourn - Agenda Item 27**

**MOTION:**

There being no further business, the Oversight Committee unanimously approved a motion to adjourn made by Presiding Officer Geren and seconded Mr. Montgomery.

Meeting adjourned at 2:55 p.m.

  
\_\_\_\_\_  
Signature 

  
\_\_\_\_\_  
Date



CANCER PREVENTION & RESEARCH  
INSTITUTE OF TEXAS

August 3, 2017

Dear Oversight Committee Members:

I am pleased to present the Program Integration Committee's (PIC) unanimous recommendations for funding 61 grant applications totaling \$104,499,137. The PIC recommendations for 52 academic research grant awards, 8 prevention awards, and 1 product development research award are attached.

Dr. Jim Willson, CPRIT's Chief Scientific Officer, Dr. Becky Garcia, CPRIT's Chief Prevention Officer, and Mr. Michael Lang, CPRIT's Chief Product Development Officer, have prepared overviews of the academic research, prevention, and product development research slates to assist your evaluation of the recommended awards. The overviews are intended to provide a comprehensive summary with enough detail to understand the substance of the proposal and the reasons endorsing grant funding. In addition to the full overviews, all of the information considered by the Review Councils is available by clicking on the appropriate link in the portal. This information includes the application, peer reviewer critiques, and the CEO affidavit for each proposal.

The PIC has recommended 12 awards that were deferred earlier in FY2017. The recommended awards include 8 Individual Investigator Research Awards, 3 Early Translational Research Awards, and 1 Competitive Continuation/Expansion award.

The approval of these grant recommendations is governed by a statutory process that requires two-thirds of the members present and voting to approve each recommendation. Vince Burgess, CPRIT's Chief Compliance Officer, will certify that the review process for the recommended grants followed CPRIT's award process prior to any Oversight Committee action.

The award recommendations will not be considered final until the Oversight Committee meeting on August 16, 2017. Consistent with the non-disclosure agreement that all Oversight Committee members have signed, the recommendations should be kept confidential and not be disclosed to anyone until the award list is publicly announced at the Oversight Committee meeting. I request that Oversight Committee members not print, email or save to your computer's hard drive any material on the portal. I appreciate your assistance in taking all necessary precautions to protect this information.

If you have any questions or would like more information on the review process or any of the projects recommended for an award, CPRIT's staff, including myself, Dr. Willson, Dr. Garcia, and Mr. Lang are always available. Please feel free to contact us directly should you have any questions. The programs that will be supported by the CPRIT awards are an important step in our efforts to mitigate the effects of cancer in Texas. Thank you for being part of this endeavor.

Sincerely,  
Wayne R. Roberts  
Chief Executive Officer

---

**PIC Recommendation**



## Academic Research Award Recommendations –

The PIC unanimously recommends approval of 52 academic research grant proposals totaling \$81,481,933. The recommended grant proposals were submitted in response to six grant mechanisms: Early Translational Research Awards; Individual Investigator Research Awards; Core Facility Research Awards; High-Impact/High-Risk Research Awards; Recruitment of First-Time, Tenure-Track Faculty Members; and Recruitment of Established Investigators. The PIC followed the recommendations made by the Scientific Review Council (SRC). The SRC provided the prioritized list of recommendations for the awards to the presiding officers on July 17, 2017.

The PIC unanimously voted to recommend 11 awards that were recommended by the SRC in cycle 17.1 and deferred by the PIC on October 28, 2016. The PIC voted to reduce the budget of each previously deferred award by 8.5%. The budget amounts, as recommended by the PIC, are reflected in the “Previously Deferred Individual Investigator Research Awards and Early Translational Research Awards” table below.

The PIC is required to give funding priority, to the extent possible, to applications that meet one or more criteria set forth in V.T.C.A., TEX. HEALTH & SAFETY CODE § 102.251(a)(2)(C). The PIC determined that these academic research proposals met the following CPRIT funding priorities:

- could lead to immediate or long-term medical and scientific breakthroughs in the area of cancer prevention or cures for cancer;
- strengthen and enhance fundamental science in cancer research;
- ensure a comprehensive coordinated approach to cancer research and cancer prevention;
- are interdisciplinary or interinstitutional;
- address federal or other major research sponsors' priorities in emerging scientific or technology fields in the area of cancer prevention or cures for cancer;
- are matched with funds available by a private or nonprofit entity and institution or institutions of higher education;
- are collaborative between any combination of private and nonprofit entities, public or private agencies or institutions in this state, and public or private institutions outside this state;
- have a demonstrable economic development benefit to this state;
  - This priority is met by the following mechanisms: Early Translational Research Awards; Individual Investigator Research Awards; Core Facility Research Awards; Recruitment of First-Time, Tenure-Track Faculty Members; and Recruitment of Established Investigators
- enhance research superiority at institutions of higher education in this state by creating new research superiority, attracting existing research superiority from institutions not located in this state and other research entities, or enhancing existing research superiority by attracting from outside this state additional researchers and resources;
- Expedite innovation and commercialization, attract, create, or expand private sector entities that will drive a substantial increase in high-quality jobs, and increase higher education applied science or Technology research capabilities; and
- address the goals of the Texas Cancer Plan.

**Academic Research Grant Award Recommendations**

<b>Core Facility Support Awards</b>						
<b>Application ID</b>	<b>Award Mechanism</b>	<b>Meeting Overall Score</b>	<b>Application Title</b>	<b>PI</b>	<b>PI Organization</b>	<b>Recommended Budget</b>
RP170638	CFSA	1.5	Cyclotron and Radiochemistry Core Facility for Pediatric Oncology	Sun, Xiankai	The University of Texas Southwestern Medical Center	\$5,648,027
RP170644	CFSA	2.1	Establish a New Cryo-Electron Microscopy Core Facility and Service for Structure Determination at UT Southwestern Medical Center	Nicastro, Daniela	The University of Texas Southwestern Medical Center	\$5,498,714
RP170628	CFSA	2.2	The University of Texas M.D. Anderson Cancer Center Science Park Flow Cytometry and Cell Imaging Core	Richie, Ellen	The University of Texas M. D. Anderson Cancer Center	\$3,693,219
RP170691	CFSA	2.2	Patient-Derived Xenograft and Advanced in Vivo Models (PDX-AIM) Core Facility	Lewis, Michael	Baylor College of Medicine	\$3,822,860
RP170719	CFSA	2.3	GCC Center for Advanced Microscopy and Image Informatics	Mancini, Michael	Texas A&M University System Health Science Center	\$5,793,075
RP170675	CFSA	2.4	Individualized Pediatric Tumor Analysis Center of Texas (INPACT)	Allen, Carl	Baylor College of Medicine	\$200,000
RP170668	CFSA	2.5	Data Science and Informatics Core for Cancer Research	Zheng, Wenjin	The University of Texas Health Science Center at Houston	\$5,846,383

PIC Recommendations  
 FY2017 (August)

High-Impact/High-Risk Research Awards						
Application ID	Award Mechanism	Meeting Overall Score	Application Title	PI	PI Organization	Recommended Budget
RP170674	HIHRRA	1.0	Regulation of Cancer Cell Migration by Secreted Protein Phosphorylation	Tagliabracci, Vincent	The University of Texas Southwestern Medical Center	\$200,000
RP170640	HIHRRA	1.9	Capitalizing on Therapeutic Liabilities in RAS-Mutant Cancers With a Rational Combination Therapy With PARP and MEK Inhibitors	Mills, Gordon	The University of Texas M. D. Anderson Cancer Center	\$200,000
RP170686	HIHRRA	1.9	A Novel Chemical Strategy to Target EGFR for Destruction	Rao, Hai	The University of Texas Health Science Center at San Antonio	\$200,000
RP170660	HIHRRA	2.1	Optogenetic Toolkit for Precise Epigenome Editing in Cancer Cells	Zhou, Yubin	Texas A&M University System Health Science Center	\$200,000
RP170734	HIHRRA	2.1	Mitochondrial DNA Instability Engages a Cancer-Related Interferon Program to Modify the Immune Microenvironment and NAD <sup>+</sup> Metabolome and Enhance Melanoma Growth	West, Andrew	Texas A&M University System Health Science Center	\$199,795
RP170699	HIHRRA	2.1	Targeting a Metabolic Reprogramming Event for the Early Prevention of Pancreatic Cancers	Tu, Benjamin	The University of Texas Southwestern Medical Center	\$200,000
RP170671	HIHRRA	2.1	Targeting a Novel Nuclease PAAN in Triple-Negative Breast Cancer	Wang, Yingfei	The University of Texas Southwestern Medical Center	\$200,000
RP170714	HIHRRA	2.2	Optimization of a Novel Class of Microtubule Stabilizers That Circumvent Multiple Drug Resistance Mechanisms Through Crystal-Structure Guided Total Synthesis	Frantz, Douglas	The University of Texas at San Antonio	\$200,000

PIC Recommendations  
FY2017 (August)

High-Impact/High-Risk Research Awards						
Application ID	Award Mechanism	Meeting Overall Score	Application Title	PI	PI Organization	Recommended Budget
RP170817	HIHRRRA	2.2	Isolation and in Situ Profiling of Circulating Tumor Cell Subpopulations Using a Hyperuniform Structured Microchip	Li, Wei	Texas Tech University	\$200,000
RP170633	HIHRRRA	2.3	The Role of the CACNA1D Calcium Channel in Melanoma	Morrison, Sean	The University of Texas Southwestern Medical Center	\$199,828
RP170752	HIHRRRA	2.4	Radiation-Induced Release of Chemotherapeutic Agents in Vivo	Gassensmith, Jeremiah	The University of Texas at Dallas	\$200,000
RP170805	HIHRRRA	2.4	Etiology and Prevention of Gastric Cancers by Mitigation of H pylori Mechanosensing	Lele, Pushkar	Texas A&M University	\$200,000
RP170797	HIHRRRA	2.4	The Preparation of Novel Phage-Displayed Macrocyclic Peptide Libraries for the Identification of Anticancer Agents	Liu, Wenshe	Texas A&M University	\$200,000
RP170696	HIHRRRA	2.7	Targeting Cathepsin L as a Selective Mechanism for the Release of Potent Anticancer Agents from Drug-Linker Conjugates	Pinney, Kevin	Baylor University	\$200,000
RP170721	HIHRRRA	2.8	Enhancing Immunotherapy of Pancreatic Cancer by Disrupting Mutant K-Ras Using CRISPR/Cas9	Bao, Gang	Rice University	\$200,000
RP170619	HIHRRRA	2.8	An Unexpected Oncometabolic Axis: Exposing Novel Regulators of Cardiac Remodeling in Leukemia	Taegtmeier, Heinrich	The University of Texas Health Science Center at Houston	\$199,744
RP170747	HIHRRRA	3.0	Noninvasive Lung Cancer Screening by Rapid Chemical Profiling of Exhaled Breath	Sun, Yuze	The University of Texas at Arlington	\$199,999
RP170653	HIHRRRA	3.1	Identify Streptococcus gallolyticus Factors Important for Promoting Colorectal Tumor Development	Xu, Yi	Texas A&M University System Health Science Center	\$200,000
RP170722	HIHRRRA	3.1	Identification of Critical Dependencies and Actionable Therapeutic Options in Smarcb1-Deficient Pediatric Tumors	Draetta, Giulio	The University of Texas M. D. Anderson Cancer Center	\$200,000

PIC Recommendations  
 FY2017 (August)

<b>Previously Deferred Individual Investigator Research Awards and Early Translational Research Awards</b>						
<b>Application ID</b>	<b>Award Mechanism</b>	<b>Meeting Overall Score</b>	<b>Application Title</b>	<b>PI</b>	<b>PI Organization</b>	<b>Recommended Budget</b>
RP170373	IIRA	2.8	HTS for covalent GTP-competitive inhibitors of KRAS G12C	Westover, Kenneth	The University of Texas Southwestern Medical Center	\$823,500
RP170086	IIRA	2.8	Tumor suppression, p53 and retrotransposons	Abrams, John	The University of Texas Southwestern Medical Center	\$816,171
RP170572	IIRA	2.8	PROBING NOVEL CONCEPTS OF THE NF-kappaB TRANSCRIPTIONAL PROGRAM IN HUMAN CANCER	D'Orso, Ivan	The University of Texas Southwestern Medical Center	\$679,458
RP170267	IIRA	2.9	Chemically based disruption of oncogenic beta-catenin activity in liver tissue	Lum, Lawrence	The University of Texas Southwestern Medical Center	\$823,500
RP170407	IIRA	2.9	Role of HDAC8 and higher order chromatin structure in melanoma metastasis and therapy	Rai, Kunal	The University of Texas M.D. Anderson Cancer Center	\$823,154
RP170179	ETRA	2.9	Chemoablation of High-Risk Oral Premalignant Lesions for Sustained Cancer Prevention	Tsai, Robert	Texas A&M University System Health Science Center	\$915,000
RP170500	ETRA	2.9	Development of next generation steroid receptor coactivator small molecule inhibitors as novel agents to target therapy-resistant breast cancer	O'Malley, Bert	Baylor College of Medicine	\$914,006
RP170090	IIRA	3.0	Novel Regulation and Function of TAK1 in Mutant Kras-driven Development of	Chiao, Paul	The University of Texas M.D. Anderson Cancer Center	\$823,500

PIC Recommendations  
FY2017 (August)

Previously Deferred Individual Investigator Research Awards and Early Translational Research Awards						
Application ID	Award Mechanism	Meeting Overall Score	Application Title	PI	PI Organization	Recommended Budget
			Pancreatic Ductal Adenocarcinoma			
RP170333	ETRA	3.0	Targeting ubiquitination for cancer therapy	Zhang, Shuxing	The University of Texas M.D. Anderson Cancer Center	\$915,000
RP170180	IIRA	3.1	Mechanistic Roles of Long Non-Coding RNA in Glioblastoma Development and Treatment	Huang, Suyun	The University of Texas M.D. Anderson Cancer Center	\$823,500
RP170172	IIRA	3.1	Targeting Therapy Resistance using Epithelial to Mesenchymal Transition (EMT) Pathways in Preclinical Claudin Low Breast Cancer Models	Rosen, Jeffrey	Baylor College of Medicine	\$823,500

**Academic Research Recruitment  
Grant Award Recommendations**

Rank	App ID	Candidate	Mechanism	Organization	Budget	Overall Score
1	RR170048	Amos, Christopher	REI	Baylor College of Medicine	\$6,000,000	1.0
2	RR170063	Woodruff, Jeffrey	RFTFM	The University of Texas Southwestern Medical Center	\$2,000,000	1.0
3	RR170079	Li, Bo	RFTFM	The University of Texas Southwestern Medical Center	\$2,000,000	1.0
4	RR170061	Arteaga, Carlos	REI	The University of Texas Southwestern Medical Center	\$6,000,000	1.4
5	RR170064	Obeng, Esther	RFTFM	The University of Texas Southwestern Medical Center	\$2,000,000	1.5
6	RR170076	Wu, Jun	RFTFM	The University of Texas Southwestern Medical Center	\$2,000,000	1.5
7	RR170054	Dickinson, Daniel	RFTFM	The University of Texas at Austin	\$2,000,000	1.6

PIC Recommendations  
 FY2017 (August)

Rank	App ID	Candidate	Mechanism	Organization	Budget	Overall Score
8	RR170059	Tsai, Kuang-Lei	RFTFM	The University of Texas Health Science Center at Houston	\$2,000,000	1.8
9	RR170068	Kim, Daehwan	RFTFM	The University of Texas Southwestern Medical Center	\$2,000,000	2.0
10	RR170051	Aguilera, Todd	RFTFM	The University of Texas Southwestern Medical Center	\$2,000,000	2.0
11	RR170047	Hancks, Dustin	RFTFM	The University of Texas Southwestern Medical Center	\$2,000,000	2.0
12	RR170055	Zheng, Siyuan	RFTFM	The University of Texas Health Science Center at San Antonio	\$2,000,000	2.0
13	RR170075	Reddy,Rohith	RFTFM	University of Houston	\$2,000,000	2.0
14	RR170062	Uribe, Rosa	RFTFM	Rice University	\$2,000,000	2.2
15	RR170050	Mu, Ping	RFTFM	The University of Texas Southwestern Medical Center	\$2,000,000	2.3

### **Prevention Award Recommendations –**

The PIC unanimously recommends approval of eight prevention grant proposals totaling \$14,019,137. The recommended grant proposals were submitted in response to the Colorectal Cancer Prevention Coalition; Competitive Continuation/Expansion-Evidence-Based Prevention Services; Evidence-Based Prevention Services; and Tobacco Control and Lung Cancer Screening Request for Applications. The Prevention Review Council (PRC) recommended eight applications to the PIC, including one award that was previously deferred by the PIC at the January 31, 2017, PIC meeting. The PRC provided its recommendation to the presiding officers on July 10, 2017. The PIC followed the recommendation of the PRC and recommended the eight awards to the Oversight Committee, including the previously deferred award.

The PIC is required to give funding priority, to the extent possible, to applications that meet one or more criteria set forth in V.T.C.A., TEX. HEALTH & SAFETY CODE § 102.251(a)(2)(C). The PIC determined that these product development proposals met the following CPRIT funding priorities:

- ensure a comprehensive coordinated approach to cancer research and cancer prevention;
- are interdisciplinary or interinstitutional;
- address federal or other major research sponsors' priorities in emerging scientific or technology fields in the area of cancer prevention, or cures for cancer;
- are collaborative between any combination of private and nonprofit entities, public or private agencies or institutions in this state, and public or private institutions outside this state;
- have a demonstrable economic development benefit to this state; and
- address the goals of the Texas Cancer Plan.



**Prevention Grant Award Recommendations**

App ID	Mech.	Application Title	PD	Organization	Score	Rank Order	Rec Budget
PP170094	EBP	Expanding a Community Network for Cancer Prevention to Improve Cervical and Colorectal Screening and Follow-Up Among an Urban Medically Underserved Population	Jibaja-Weiss, Maria L	Baylor College of Medicine	1.2	1	\$1,347,590
PP170068	CRC	Southwest Coalition for Colorectal Cancer Screening (SuCCCeS)	Shokar, Navkiran K	Texas Tech University Health Sciences Center at El Paso	1.7	2	\$3,679,823
PP170070	TCL	Taking Texas Tobacco Free: Increasing Tobacco Cessation In Substance Use Treatment Centers via an Evidence-based, Comprehensive Tobacco-free Workplace Program	Reitzel, Lorraine R	University of Houston	2.0	3	\$1,348,851
PP170082	CRC	Improving Colorectal Cancer Screening in Vulnerable Populations in Travis County	Pignone, Michael	The University of Texas at Austin	2.1	4	\$2,292,971
PP170099	TCL	Mobile Cessation Services for Young Adult Rural, Low-Income, and Spanish-Speaking Smokers	Ramirez, Amelie G	The University of Texas Health Science Center at San Antonio	2.2	5	\$1,302,641
PP170088	EBP	Access to Breast and Cervical Care for West Texas (ABC24WT)	Layeequr Rahman, Rakhshanda	Texas Tech University Health Sciences Center	2.4	6	\$1,349,730
PP170091	EBP	Empower Her To Care Expansion(EHC4):Increasing Access to Breast Cancer Screening and the Continuum of Care for Underserved Texas Women	Joseph, Bernice	The Rose	3.1	7	\$1,347,531
PP170037 Deferred from 17.1	CCE-EBP	Continuation/Expansion of Texas A&M's Breast and Cervical Cancer Prevention Program for Underserved Women	McClellan, David A	Texas A&M University System Health	3.4	8	\$1,350,000

PIC Recommendations  
FY2017 (August)

---

		through a Family Medicine Residency		Science Center			
--	--	--	--	-------------------	--	--	--

## **Product Development Research Award Recommendations –**

The PIC unanimously recommends approval of one product development research grant proposal totaling \$8,998,067. The recommended grant proposal was submitted in response to the Texas Company Product Development Research Awards Request for Applications. The Product Development Review Council (PDRC) recommended one application to the PIC. The PDRC provided its recommendation to the presiding officers on July 24, 2017.

The PIC is required to give funding priority, to the extent possible, to applications that meet one or more criteria set forth in V.T.C.A., TEX. HEALTH & SAFETY CODE § 102.251(a)(2)(C). The PIC determined that these product development proposal met the following CPRIT funding priorities:

- could lead to immediate or long-term medical and scientific breakthroughs in the area of cancer prevention or cures for cancer;
- ensure a comprehensive coordinated approach to cancer research and cancer prevention;
- are interdisciplinary or interinstitutional;
- are matched with funds available by a private or nonprofit entity and institution or institutions of higher education;
- are collaborative between any combination of private and nonprofit entities, public or private agencies or institutions in this state, and public or private institutions outside this state;
- have a demonstrable economic development benefit to this state;
- enhance research superiority at institutions of higher education in this state by creating new research superiority, attracting existing research superiority from institutions not located in this state and other research entities, or enhancing existing research superiority by attracting from outside this state additional researchers and resources;
- expedite innovation and product development, attract, create, or expand private sector entities that will drive a substantial increase in high-quality jobs, and increase higher education applied science or technology research capabilities; and
- address the goals of the Texas Cancer Plan.

**Product Development Research  
Grant Award Recommendation**

<b>Rank</b>	<b>Application ID</b>	<b>Company Name</b>	<b>Project</b>	<b>Maximum Recommended Budget</b>	<b>Overall Score</b>
1	DP170043	ViraCyte, LLC	Improving the Outcome of Stem Cell Transplants for Cancer Treatment Using Multi-Virus Specific T cells	\$8,998,067	1.8





CANCER PREVENTION & RESEARCH  
INSTITUTE OF TEXAS

August 9, 2017

Oversight Committee Members,

Pursuant to 25 T.A.C. § 703.7(j), I request that the Oversight Committee approve authority for CPRIT to advance grant funds upon execution of grant contracts for one company that will be considered for a Product Development grant award at the August 16, 2017, Oversight Committee meeting. The company has been recommended for a grant award by the Program Integration Committee (PIC). The Oversight Committee will consider the PIC's recommendation at the August 16, 2017, Oversight Committee meeting.

Although CPRIT disburses the majority of grant funds pursuant to requests for reimbursement, CPRIT may disburse grant funds in advance payments consistent with the General Appropriations Act, Article IX, § 4.03(a). Typically, the grant amount to be paid in advance is based upon the project year budget or tranche amount. All grant recipients, including those that receive advance payment of grant funds, are required to submit quarterly financial status reports that are reviewed and approved by CPRIT's financial staff. Failure to submit the financial status reports on a timely basis will result in forfeiture of reimbursement for expenses for the quarter and may result in grant termination and repayment of grant funds.

Advance payment of grant funds are needed for this award because it primarily funds a Phase 2 clinical trial. Most drug development firms engage the services of Clinical Research Organizations to conduct their clinical studies. The cost structure for these contracted services is highly front loaded. Hence the Clinical Research service providers typically require substantial upfront payments. Advancing grant funds allows these projects to begin work as quickly as possible.

Sincerely,

Wayne R. Roberts,  
CPRIT Chief Executive Officer



---

**CANCER PREVENTION & RESEARCH  
INSTITUTE OF TEXAS**

**A RESOLUTION  
AUTHORIZING THE TRANSFER OF  
MANAGEMENT AND DISPOSITION AUTHORITY FOR CERTAIN ASSETS TO  
THE TEXAS TREASURY SAFEKEEPING TRUST COMPANY  
AND THE PAYMENT OF A FEE  
FOR MANAGEMENT OF THE ASSETS**

**Whereas**, Texas Health & Safety Code § 102.256 authorizes the Cancer Prevention and Research Institute of Texas (“CPRIT”) to collect royalties, income, and other benefits, including interest or proceeds resulting from securities or equity, realized because of projects undertaken with CPRIT grant awards;

**Whereas**, CPRIT owns equity in publicly traded and privately held companies pursuant to contractual agreements authorized by Texas Health & Safety Code § 102.256;

**Whereas**, the 85<sup>th</sup> Session of the Texas Legislature adopted an amendment to Texas Health & Safety Code § 102.256, signed into law by the Governor on June 9, 2017, and effective September 1, 2017, (“Authorizing Law”) permitting CPRIT to transfer to the Texas Treasury Safekeeping Trust Company (“Trust Company”) CPRIT’s management and disposition authority over the state’s interest in securities, equities, royalties, income, and other benefits realized as a result of projects undertaken with CPRIT grant awards;

**Whereas**, in managing the assets transferred by CPRIT through procedures and subject to restrictions that the Trust Company considers appropriate, the Trust Company may acquire, exchange, sell, supervise, manage, or retain any kind of investment that a prudent investor, exercising reasonable care, skill, and caution, would acquire, exchange, sell, or retain in light of the purposes, terms, distribution requirements, and other circumstances then prevailing pertinent to each investment, including the requirements prescribed by Texas Health & Safety Code § 102.256(b) and the purposes described by Texas Health & Safety Code § 102.002;

**Whereas**, the CPRIT Oversight Committee desires and intends to transfer its management and disposition authority over specific equity interests realized as a result of certain CPRIT grant awards as permitted by Authorizing Law; and

**Whereas**, Authorizing Law permits the Trust Company to charge CPRIT a fee to recover the reasonable and necessary costs incurred in managing the assets transferred by CPRIT.

**NOW, THEREFORE, BE IT RESOLVED** by the CPRIT Oversight Committee that:

Section 1. The CPRIT Oversight Committee intends to transfer its management and disposition authority for, the assets listed below to the Trust Company effective on or after September 1, 2017, in accordance with applicable local law and relevant constitutional documents of the companies whose shares are to be transferred. Accordingly and pursuant to the Authorizing Law, the CPRIT Oversight Committee hereby ratifies, approves, and confirms the transfer of the following assets listed below:

- a. All shares held by CPRIT in Cell Medica Limited (approximately 1,822,437 A Preference Shares)
- b. All shares held by CPRIT in Mirna Therapeutics (approximately 2,395,010 shares of common stock);
- c. All shares held by CPRIT in Codiak Biosciences, Inc. (approximately 112,500 shares of Series A Preferred Stock and 432,750 shares of Class A Common Stock); and
- d. All shares held by CPRIT in Coregon, Inc. (approximately 333,333 shares of common stock).

Section 2. In the event that the shares of one or more companies listed herein is exchanged for shares in another company through a merger or acquisition on or after the date of this resolution, the CPRIT Oversight Committee affirms that the transfer of management and disposition authority as described in this resolution and approved by the CPRIT Oversight Committee specifically applies to the shares of the new company without further action by the CPRIT Oversight Committee.

Section 3. The CPRIT Oversight Committee hereby delegates authority to CPRIT's Chief Executive Officer, and any designee of the Chief Executive Officer, to take all action in conformity with the Authorizing Law necessary to effect the transfer of CPRIT's management and disposition authority for, the specific assets named herein to the Trust Company on or after September 1, 2017. CPRIT's Chief Executive Officer, and any designee of the Chief Executive Officer, may take all action necessary or desirable in conformity with the Authorizing Law for carrying out, giving effect to, and consummating the transactions required to complete the transfer. Such authority includes, without limitation, the execution and delivery of any documents in connection with the transfer and the negotiation and payment of a fee paid by CPRIT to the Trust Company for the reasonable and necessary costs incurred in managing the transferred assets.

Section 4. The CPRIT Oversight Committee hereby empowers, authorizes, and directs CPRIT's Chief Executive Officer to:

- a. sign and deliver any and all documents necessary or desirable to effect the transfer of authority to the Trust Company. Such documents may include but not limited to a Memorandum of Understanding and Fee Agreement between CPRIT and the Trust Company;
- b. cooperate with the named companies, including their successors, the Trust Company and its consultants to effectuate the transfer; and
- c. to take any other action necessary to assist in such transfer.

Section 5. The CPRIT Oversight Committee hereby ratifies, approves, and confirms all actions consistent with provisions of this Resolution heretofore taken by CPRIT and its Chief



Executive Officer or designee thereof and the other officers of, or consultants to CPRIT, directed toward the transfer of the specific assets named herein.


Section 6. The CPRIT Oversight Committee adopted this Resolution at a meeting open to the public, and CPRIT provided public notice of the time, place, and purpose of said meeting, all as required by Ch. 551, Texas Government Code.

Adopted by the affirmative vote of a majority of the CPRIT Oversight Committee present and voting on August 16, 2017.

Cancer Prevention and Research Institute  
of Texas Oversight Committee

Attested:

 8/16/2017



Chairman

Secretary

